Indian Patent Office Rejects TB Alliance's Patent on BPaL Regimen Under Sections 3(d), 3(e), 3(i)
The Indian Patent Office has rejected a patent application for the BPaL (Bedaquiline, Pretomanid, Linezolid) drug regimen for drug-resistant tuberculosis, citing lack of inventive step under India's Patents Act. This decision upholds key public health safeguards (Sections 3(d), 3(e), 3(i)) and concerns a WHO-recommended, six-month oral treatment. It is a significant development in India's fight against TB, which accounts for a quarter of global cases.
28 October 2026,

